Related Experiment Video
Updated: Oct 20, 2025
The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
Published on: November 19, 2008
Current Therapies for Neonatal Hypoxic-Ischaemic and Infection-Sensitised Hypoxic-Ischaemic Brain Damage
Konstantina Tetorou1, Claudia Sisa1, Arzo Iqbal1
1Perinatal Brain Repair Group, Department of Maternal and Fetal Medicine, UCL Institute for Women's Health, London, United Kingdom.
Insights
Neonatal hypoxic-ischaemic brain injury is a major cause of disability. This review explores infection-sensitised brain injury and examines new treatments beyond therapeutic hypothermia.
Area of Science:
- Neuroscience
- Neonatal Medicine
- Developmental Biology
Background:
- Neonatal hypoxic-ischaemic (HI) brain damage causes significant mortality, morbidity (cerebral palsy, epilepsy, cognitive disabilities), and is linked to impaired fetal perfusion.
- Bacterial infection, present in over half of preterm births, exacerbates HI injury, creating 'infection-sensitised' brain injury.
- Existing animal models and human studies indicate that brain vulnerability and outcomes depend on developmental stage and HI severity.
Purpose of the Study:
- To review the mechanisms of hypoxic-ischaemic brain injury in immature brains.
- To discuss novel experimental treatments for neonatal HI and infection-sensitised HI.
- To highlight the need for improved treatments given the limitations of current therapeutic hypothermia (TH).
Main Methods:
- Literature review of mechanisms underlying neonatal hypoxic-ischaemia.
- Analysis of experimental studies on therapeutic interventions for neonatal brain injury.
- Synthesis of findings on infection-sensitised hypoxic-ischaemic brain injury.
Main Results:
- Therapeutic hypothermia (TH) is the sole approved treatment but requires treating 6-7 infants to benefit one.
- Infection significantly worsens HI brain damage.
- Brain vulnerability and clinical manifestations are influenced by developmental stage and insult severity.
Conclusions:
- Additional or alternative treatments are crucial to improve outcomes for neonatal HI.
- Understanding infection-sensitised HI mechanisms is key to developing more effective therapies.
- Further research into novel experimental treatments is warranted to address the limitations of current approaches.
Abstract:
Neonatal hypoxic-ischaemic brain damage is a leading cause of child mortality and morbidity, including cerebral palsy, epilepsy, and cognitive disabilities. The majority of neonatal hypoxic-ischaemic cases arise as a result of impaired cerebral perfusion to the foetus attributed to uterine, placental, or umbilical cord compromise prior to or during delivery. Bacterial infection is a factor contributing to the damage and is recorded in more than half of preterm births. Exposure to infection exacerbates neuronal hypoxic-ischaemic damage thus leading to a phenomenon called infection-sensitised hypoxic-ischaemic brain injury. Models of neonatal hypoxia-ischaemia (HI) have been developed in different animals. Both human and animal studies show that the developmental stage and the severity of the HI insult affect the selective regional vulnerability of the brain to damage, as well as the subsequent clinical manifestations. Therapeutic hypothermia (TH) is the only clinically approved treatment for neonatal HI. However, the number of HI infants needed to treat with TH for one to be saved from death or disability at age of 18-22 months, is approximately 6-7, which highlights the need for additional or alternative treatments to replace TH or increase its efficiency. In this review we discuss the mechanisms of HI injury to the immature brain and the new experimental treatments studied for neonatal HI and infection-sensitised neonatal HI.
